Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Study Finds No Safety or Immunogenicity Differences in Patients Switching Patients Between Reference Biologics and Biosimilars

Oct 3, 2023

A PLOS One study found that there was no difference in the safety profiles or immunogenicity rates in patients who were switched and those who remained on a reference biologic or a biosimilar. The study examined unique studies and switch treatment periods for each reference biologic with an FDA approved biosimilar, including AbbVie’s Humira® (adalimumab), Amgen’s Epogen® (epoetin-alfa), Amgen’s Enbrel® (etanercept), Amgen’s Neupogen® (filgrastim), Sanofi’s Lantus® (insulin-glargine), Genentech/Biogen’s Rituxan® (rituximab) and Genentech’s Herceptin® (trastuzumab).

On 26 May 2023, a study published in JAMA Network Open found in a systematic review and meta-analysis that biosimilars of adalimumab, etanercept, and infliximab were associated with clinically equivalent effects in patients with rheumatoid arthritis compared with their reference biologics.